Antipsychotic drug side effects for persons with intellectual disability.

Hilton et al. (2010) read every paper they could find on antipsychotic side effects in people with intellectual disability. They did not run a new experiment. They wrote a story-style review to tell doctors what tools exist to spot these side effects.

The authors focused on two checklists: MEDS and DISCUS. They said teams should use these scales instead of just asking, 'Any problems?' at check-up time.

The review found no hard numbers. Instead, it gave a clear message: use a structured scale every time. The paper ends with a plea—stop guessing and start measuring.

They warned that people with ID may not report dizziness, tics, or sedation on their own, so staff must watch and score.

Congiu et al. (2010) took the advice and ran with it. They used MEDS in a real study and showed that adults taking more psychotropic classes scored higher on side effects. This gives the first data that the checklist actually catches extra harm.

Dell'Armo et al. (2024) looked at the same crowd but asked a different question: are doctors missing mental-health diagnoses because they blame everything on ID? Their answer was mixed—only some studies found this ‘diagnostic overshadowing.’ The two papers seem to clash—one says ‘watch the drug,’ the other says ‘watch the bias’—but they really just highlight two different holes in the same boat.

Hudson et al. (2012) widened the lens to kids with autism. They found almost no solid trials for most psychotropics. Together, these reviews form a ladder: first prove the drug is needed, then track side effects with a scale, and still stay alert for missed diagnoses.

If you serve adults or children with ID, pick a side-effect scale today—MEDS is free, DISCUS is short. Add it to every Medication Administration Record. One extra minute of scoring beats weeks of untreated tremors, weight gain, or sedation that clients cannot describe in words.